Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- Status Of Ryan White Program Examined
- Drinks Industry Supplanting Government Role In Alcohol Policies In Sub-Saharan Africa
- Cancer-Causing Virus Associated With Higher Risk Of New HIV Infection
- Wisconsin Issues HIV/AIDS Nonprofit Directives For Corrective Action; Clients Protest Service Inadequacies
- New Survey Targets Over 50s Living With HIV, UK
- GPs Key To Meeting HIV Changes And Challenges, Australian
- Obesity May Have Adverse Role In HIV Treatment
- IRIN/Plus News Examines HIV/AIDS Services In Zimbabwe Following Economic Crisis
- 'Shock And Kill' Research Gives New Hope For HIV 1 Eradication
- Blogs Comment On Obama's Health Reform Speech, Baucus' Reform Proposal, Other Topics
Prescription AIDS Drugs
Contact Us
Obesity May Have Adverse Role In HIV Treatment
March 27th, 2010
The immune systems of HIV patients who are obese don’t respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
“Obese patients were found to regain fewer CD4-positive T cells after they start therapy than do people with normal weight,” said Dr. Crum-Cianflone. “These findings don’t align with some of the earlier studies done prior to the advent of modern highly active antiretroviral therapy (HAART), when patients who were obese did better than those of normal or below-normal weight,” she said. According to Crum-Cianflone, this recent data may imply that obesity — which has known ill effects — poses an additional risk to people with HIV.
This research was based on data collected by the USU’s Infectious Disease Clinical Research Program (IDCRP) from participants in the U.S. Military Natural History Study, which includes 1,119 people with documented dates of HIV seroconversion between 1986 and 2008.
“The irony is that in the past we have been concerned that patients with HIV infection were losing too much weight,” said Captain (Dr.) Greg Martin, director of the IDCRP, “yet this research is showing that there needs to be more of a focus on maintaining a balanced weight without going to the other extreme.”
Previous research has shown that prior to the availability of HAART, patients who were obese lost CD4 cells — a hallmark of HIV infection — more slowly than people who had normal or below-normal weight.
The use of HAART results in immune system recovery, measured by an increase in the number of CD4 cells, Crum-Cianflone noted.
The study “suggests that low CD4 counts may be another adverse consequence of obesity,” she said, adding that patients should work toward maintaining a normal weight. Crum-Cianflone said it’s not clear why obesity should have such an effect.
Among other possibilities, she said, it might be that standard drug dosing — set in clinical trials — may not be enough for obese patients, or there may be something about the extra weight that limits the effects of medications.
Source: Uniformed Services University of the Health Sciences
Related posts:
- Raltegravir Combination Treatment For HIV Is A Safe And Effective Alternative To Efavirenz In Treatment-Naive Patients Use of the HIV antiretroviral treatment raltegravir, in combination with...
- Sperm May Play Leading Role In Spreading HIV Sperm, and not just the fluid it bathes in, can...
- Drinks Industry Supplanting Government Role In Alcohol Policies In Sub-Saharan Africa A recent comparison of proposed national alcohol policies in Lesotho,...
- Schering-Plough Expands Vicriviroc Phase II Study In Treatment-Naive Patients With HIV Schering-Plough Corporation (NYSE: SGP) announced that it has extended to...
- Directly Observed Antiretroviral Therapy Offers No Benefit Over Self-Administered Treatment For HIV Patients Directly observed antiretroviral therapy-in which a health worker or other...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.





